ACADIA Pharmaceuticals
ACAD
19.65
-0.09
-0.46%
ACADIA Pharmaceuticals
US · ACAD
#2404 by market cap
Listed 1970
19.65
-0.09
-0.46%
Live - 5344 symbols - heartbeat 222s ago
· 2026-10-08 07:15
Pre-market
19.80
+0.75%
After-hours
19.70
+0.25%
- Market cap
- 3.39B
- P/E (TTM)i
- 8.81
- P/Bi
- 2.59
- EPSi
- 2.30
- Div yieldi
- 0.00%
- 52W posi
- 2%
Reader sentiment
Are you bullish or bearish on ACAD?
Anonymous reader poll. Unscientific, not investment advice.
Analyst consensus 13 analysts
Buy
Avg price target
33.85 +72.3%
Price target rangecurrent 19.65
Low25.00
Avg33.85
High49.00
Buy 85%
Hold 15%
Sell 0%
Recent ratings (25)
| Date | Firm | Analyst | Rating | Target |
|---|---|---|---|---|
| 2026-10-05 | RBC Capital | -- | BUY | 37.00 |
| 2026-09-25 | CCORF | -- | BUY | 36.00 |
| 2026-09-25 | Citizens JMP | -- | BUY | 33.00 |
| 2026-09-25 | Deutsche Bank | -- | BUY | 31.00 |
| 2026-09-25 | Needham | -- | BUY | 35.00 |
| 2026-09-25 | BMO Capital | -- | BUY | 34.00 |
| 2026-09-25 | Citi | -- | BUY | 33.00 |
| 2026-09-25 | H.C. Wainwright | -- | BUY | 33.00 |
| 2026-09-24 | BofA Securities | -- | BUY | 31.00 |
| 2026-09-24 | Needham | -- | BUY | 41.00 |
| 2026-09-24 | Citi | -- | BUY | 33.00 |
| 2026-09-03 | CCORF | -- | BUY | 36.00 |
| 2026-08-25 | Deutsche Bank | -- | BUY | 38.00 |
| 2026-08-25 | Citi | -- | BUY | 40.00 |
| 2026-08-25 | H.C. Wainwright | -- | BUY | 37.00 |
| 2026-08-24 | BMO Capital | -- | BUY | 36.00 |
| 2026-08-18 | UBS | -- | BUY | 49.00 |
| 2026-08-18 | BMO Capital | -- | BUY | 36.00 |
| 2026-08-17 | UBS | -- | BUY | 49.00 |
| 2026-08-12 | CCORF | -- | BUY | 36.00 |
| 2026-08-12 | Needham | -- | BUY | 41.00 |
| 2026-08-10 | Citi | -- | BUY | 39.00 |
| 2026-08-05 | TD Cowen | -- | BUY | 37.00 |
| 2026-08-05 | CCORF | -- | BUY | 36.00 |
| 2026-08-05 | BofA Securities | -- | BUY | 31.00 |
Quant vs Street three independent views, side by side
Momentum strategy signal
Sell
Analyst consensus
Buy
Signals diverge - worth digging into why.
Not investment advice. The factor grade ranks this stock on fundamentals against StockVane's covered universe; the momentum strategy signal is a rules-based backtest, not a recommendation; analyst consensus reflects sell-side coverage. The three use different methods and can reasonably disagree.
Price target trend monthly average, last 3 years
✦ Quant Analyst Revision Trend how this is computed
Mixed
1
■ Upgrades■ Downgrades
- 1 upgrade vs 0 downgrades among tracked analyst rating changes.
- Most recent: BofA Securities moved from Hold to Buy on 2026-03-25.
Recent rating changes
| Date | Firm | Change | Target |
|---|---|---|---|
| 2026-03-25 | BofA Securities | HOLD → BUY | 29.00 |
Earnings history price reaction on the day
| Period | Report date | Session | Options expected | Actual move |
|---|---|---|---|---|
| 2026/Q2 | 2026-08-04 | After close | ±9.58% | +6.08% (in line) |
| 2026/Q1 | 2026-05-06 | After close | ±7.06% | +5.03% (in line) |
| 2025/Q4 | 2026-02-25 | After close | ±9.52% | -1.32% (in line) |
| 2025/Q3 | 2025-11-05 | After close | ±12.70% | -3.05% (in line) |
| 2025/Q2 | 2025-08-06 | After close | ±10.61% | +2.52% (in line) |
| 2025/Q1 | 2025-05-07 | After close | ±13.22% | +14.31% (beat) |
| 2024/Q4 | 2025-02-26 | After close | ±14.04% | +1.79% (in line) |
| 2024/Q3 | 2024-11-06 | After close | ±15.79% | +8.93% (in line) |
| 2024/Q2 | 2024-08-06 | After close | ±20.38% | -19.52% (in line) |
| 2024/Q1 | 2024-05-08 | After close | ±17.34% | -11.21% (in line) |
| 2023/Q4 | 2024-02-27 | After close | ±15.33% | -9.92% (in line) |
| 2023/Q3 | 2023-11-02 | After close | ±10.32% | +4.70% (in line) |
"Options expected" is the pre-earnings options market's implied move (a straddle-style estimate), shown next to what actually happened.
Quote time 2026-10-08 07:15:07 · For reference only, not investment advice and not tailored to your situation.